Sophia Genetics said that it has received CE-IVD marking for analytics functionality of its core Sophia Data Driven Medicine (DDM) software platform. The Swiss-American firm made the announcement Tuesday at the European Society of Human Genetics conference in Vienna.

Currently, there is a shortage of monkeys in the china pharmaceutical industry, and pharmaceutical R & D enterprises are purchasing lab monkeys on a large scale.

OncoHost will use SomaLogic's SomaScan platform to develop proteomic tests for OncoHost's Prophet diagnostic system to predict patient response to immunotherapy treatments and develop strategies to overcome treatment resistance, the two firms announced on Monday.

Because of the COVID-19 epidemic, the IVD industry has developed rapidly in the past two years, a large amount of capital and talents have poured in. However, with the normalization of epidemic prevention and control, the IVD industry is also returning to the original normal track.

Roche subsidiary Foundation Medicine announced on Thursday that its FoundationOne CDx test has been approved by the US Food and Drug Administration as a companion diagnostic with Roche's Rozlytrek (entrectinib).

By the year 2030, pancreatic cancer is expected to become the second most common cause of cancer deaths for both men and women in the United States, according to recent reports. While considered uncommon, inherited gene mutations can increase a person’s risk of developing pancreatic cancer.

Pfizer Inc. announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment.

A study of 1.3 million women in England has provided evidence to support the extension of cervical cancer screening intervals from three years to five years for those that have a negative screen result.

LumiraDx on Thursday announced it has obtained CE marking for its five-minute SARS-CoV-2 Ag Ultra Test.

On May 18, the treatment report of the first Chinese produced SARS-CoV-2 oral drug was announced.